Professor Chiara Braconi
- Chair in Hepatobiliary Oncology (Clinical Research Garscube)
email:
Chiara.Braconi@glasgow.ac.uk
Wolfson Wohl Cancer Research Centre, Switchback road, Glasgow, G61 1BD
https://orcid.org/0000-0003-4835-1259Biography
Chiara Braconi is a Lord Kelvin Adam Smith Reader in the Institute of Cancer Sciences and holds a honorary contract as Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre.
Her research is focused on hepato-pancreatico-biliary tumours, and aims at delineating novel treatment strategies for these cancers by integrating genomics, epigenomics and patient derived models for the identification of novel therapeutic targets and biomarkers.
Dr Braconi received her MD degree from the University of Ancona in Italy, and completed her fellowship in Medical Oncology in 2006. She then enrolled in a joint PhD program between the University of Ancona and The Ohio State University, which was followed by post-doctoral training at the Ohio State University, USA.
She worked at the University of Glasgow between 2012 and 2014 supported by a Scottish Senior Clinical Research Fellowship, where she continued her work on the role of non-coding RNAs in hepatobiliary cancers.
In 2014 she joined the Institute of Cancer Research / Royal Marsden Hospital in London as a clinician scientist where she integrated the study of molecular biology with clinical research to sustain a patient-oriented programme in biliary-pancreatic cancers. She combined the study of transcriptional and post-transcriptional modifications with patient derived organoids to inform drug discovery and biomarker development.
She has joined the Institute of Cancer Sciences in May 2019 where she will develop a research platform on biliary cancers, connecting laboratory research and early clinical development in order to accelerate the field of predictive biomarkers and therapeutics.
She is currently working within national and international consortia (European Network for the Study of Cholangiocarcinoma, COST-action 18122, and Cholangiocarcinoma-UK) to support a collaborative international research programme in biliary cancers.
Research interests
Research groups
- Upper GI (cholangiocarcinoma/biliary cancers/hepatobiliary)
Publications
2024
Kendall, T., Overi, D., Guido, M., Braconi, C. , Banales, J., Cardinale, V., Gaudio, E., Groot Koerkamp, B. and Carpino, G. (2024) Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma. JHEP Reports, 6(6), 101067. (doi: 10.1016/j.jhepr.2024.101067) (PMID:38699072) (PMCID:PMC11060959)
Zanuso, V., Nash, T., Casolino, R., Armstrong, G., Pallise, O., Milne, J. and Braconi, C. (2024) Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic. BMC Cancer, 24(1), 597. (doi: 10.1186/s12885-024-12279-6) (PMID:38755562) (PMCID:PMC11097428)
O’Rourke, C. J. et al. (2024) Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut, 73(3), pp. 496-508. (doi: 10.1136/gutjnl-2023-330748) (PMID:37758326) (PMCID:PMC10894814)
2023
Zanuso, V., Rimassa, L. and Braconi, C. (2023) The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology, (doi: 10.1097/HEP.0000000000000572) (PMID:37695554) (Early Online Publication)
Vita, F., Olaizola Rebè, I., Amato, F., Rae, C. , Marco, S., Banales, J. M. and Braconi, C. (2023) Heterogeneity of cholangiocarcinoma immune biology. Cells, 12(6), 846. (doi: 10.3390/cells12060846) (PMID:36980187) (PMCID:PMC10047186)
2022
Raggi, C., Taddei, M. L., Rae, C. , Braconi, C. and Marra, F. (2022) Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 77(3), pp. 849-864. (doi: 10.1016/j.jhep.2022.04.038) (PMID:35594992)
Muñoz‐Martínez, S. et al. (2022) Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study. Liver International, 42(8), pp. 1891-1901. (doi: 10.1111/liv.15320) (PMID:35608939)
Colyn, L. et al. (2022) New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 41, 183. (doi: 10.1186/s13046-022-02386-2) (PMID:35619118) (PMCID:PMC9134609)
Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)
Casolino, R. et al. (2022) Bridging the equity gap in patient education: the biliary tract cancer BABEL project. Lancet Oncology, 23(5), pp. 568-570. (doi: 10.1016/S1470-2045(22)00143-7) (PMID:35489338)
Izquierdo-Sanchez, L. et al. (2022) Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 76(5), pp. 1109-1121. (doi: 10.1016/j.jhep.2021.12.010) (PMID:35167909)
2021
Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)
Lampis, A. et al. (2021) MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 28, pp. 2970-2982. (doi: 10.1038/s41418-021-00820-0) (PMID:34226680) (PMCID:PMC8481293)
Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)
Rae, C. , Amato, F. and Braconi, C. (2021) Patient-derived organoids as a model for cancer drug discovery. International Journal of Molecular Sciences, 22(7), 3483. (doi: 10.3390/ijms22073483) (PMID:33801782) (PMCID:PMC8038043)
Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)
Ofoeyeno, N., Ekpenyong, E. and Braconi, C. (2021) Pathogenetic role and clinical implications of regulatory RNAs in biliary tract cancer. Cancers, 13(1), 12. (doi: 10.3390/cancers13010012) (PMID:33375055) (PMCID:PMC7792779)
Pea, A., Jamieson, N. B. and Braconi, C. (2021) Biology and clinical application of regulatory RNAs in hepatocellular carcinoma. Hepatology, 73(S1), pp. 38-48. (doi: 10.1002/hep.31225) (PMID:32160335)
2020
Marin, J. J. G. et al. (2020) Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 123, pp. 1047-1059. (doi: 10.1038/s41416-020-0987-3) (PMID:32694694)
Carotenuto, P. et al. (2020) Modulation of biliary cancer chemo‐resistance through microRNA‐mediated rewiring of the expansion of CD133+ cells. Hepatology, 72(3), pp. 982-996. (doi: 10.1002/hep.31094) (PMID:31879968) (PMCID:PMC7590111)
McNamara, M. G. et al. (2020) NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 16(16), pp. 1069-1081. (doi: 10.2217/fon-2020-0247) (PMID:32374623)
Amato, F., Rae, C. , Prete, M. G. and Braconi, C. (2020) Cholangiocarcinoma disease modelling through patients derived organoids. Cells, 9(4), 832. (doi: 10.3390/cells9040832) (PMID:32235647) (PMCID:PMC7226733)
2019
Salati, M. et al. (2019) The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. European Journal of Cancer, 117, pp. 84-90. (doi: 10.1016/j.ejca.2019.05.030) (PMID:31276980)
Salati, M., Valeri, N., Spallanzani, A., Braconi, C. and Cascinu, S. (2019) Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 45(8), pp. 1479-1482. (doi: 10.1016/j.ejso.2018.11.006) (PMID:30448343)
Anandappa, G. et al. (2019) miR-31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. Clinical Cancer Research, 25(13), pp. 3830-3838. (doi: 10.1158/1078-0432.ccr-18-3769) (PMID:30952636)
Banales, J. M., Cardinale, V., Macias, R., Andersen, J. B., Braconi, C. , Carpino, G., Alvaro, D. and Calvisi, D. F. (2019) Cholangiocarcinoma: state‐of‐the‐art knowledge and challenges. Liver International, 39(S1), pp. 5-6. (doi: 10.1111/liv.14101) (PMID:31111668)
Braconi, C. , Roessler, S., Kruk, B., Lammert, F., Krawczyk, M. and Andersen, J. B. (2019) Molecular perturbations in cholangiocarcinoma: is it time for precision medicine? Liver International, 39(S1), pp. 32-42. (doi: 10.1111/liv.14085) (PMID:30829432)
Khan, K. et al. (2019) Efficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience. Clinical Colorectal Cancer, 18(1), 64-71.e1. (doi: 10.1016/j.clcc.2018.09.010) (PMID:30404764)
Fassan, M. et al. (2019) miR-224 is significantly upregulated and targets caspase-3 and caspase-7 during colorectal carcinogenesis. Translational Oncology, 12(2), pp. 282-291. (doi: 10.1016/j.tranon.2018.10.013) (PMID:30448733) (PMCID:PMC6240712)
Salati, M. and Braconi, C. (2019) Noncoding RNA in cholangiocarcinoma. Seminars in Liver Disease, 39(1), pp. 13-25. (doi: 10.1055/s-0038-1676097) (PMID:30536290)
2018
Khan, K. H. et al. (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discovery, 8(10), pp. 1270-1285. (doi: 10.1158/2159-8290.CD-17-0891) (PMID:30166348) (PMCID:PMC6380469)
Khan, K. et al. (2018) Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 67(8), pp. 1484-1492. (doi: 10.1136/gutjnl-2017-314178) (PMID:28790159) (PMCID:PMC6204951)
Saraggi, D. et al. (2018) MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. Pathology: Research and Practice, 214(6), pp. 835-839. (doi: 10.1016/j.prp.2018.04.018) (PMID:29731265)
Lampis, A. et al. (2018) MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology, 154(4), 1066-1079.e5. (doi: 10.1053/j.gastro.2017.10.043) (PMID:29113809) (PMCID:PMC5863695)
Vlachogiannis, G. et al. (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359(6378), pp. 920-926. (doi: 10.1126/science.aao2774) (PMID:29472484) (PMCID:PMC6112415)
Sclafani, F. et al. (2018) KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 8, 1445. (doi: 10.1038/s41598-018-19212-5) (PMID:29362371) (PMCID:PMC5780472)
Moorcraft, S. Y. et al. (2018) Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Annals of Oncology, 29(1), pp. 230-236. (doi: 10.1093/annonc/mdx631) (PMID:29361134)
2017
Ghidini, M. et al. (2017) Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 86, pp. 158-165. (doi: 10.1016/j.ejca.2017.09.005) (PMID:28988016) (PMCID:PMC5699791)
Ghidini, M., Tomasello, G., Botticelli, A., Barni, S., Zabbialini, G., Seghezzi, S., Passalacqua, R., Braconi, C. and Petrelli, F. (2017) Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB, 19(9), pp. 741-748. (doi: 10.1016/j.hpb.2017.05.010) (PMID:28684194)
Kayhanian, H., Smyth, E. C. and Braconi, C. (2017) Emerging molecular targets and therapy for cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 9(7), pp. 268-280. (doi: 10.4251/wjgo.v9.i7.268) (PMID:28808500) (PMCID:PMC5534395)
Lote, H. et al. (2017) Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of Oncology, 28(6), pp. 1243-1249. (doi: 10.1093/annonc/mdx074) (PMID:28327965) (PMCID:PMC5452067)
Pepe, F., Pagotto, S., Soliman, S., Rossi, C., Lanuti, P., Braconi, C. , Mariani-Costantini, R., Visone, R. and Veronese, A. (2017) Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells. Oncogenesis, 6(5), e328. (doi: 10.1038/oncsis.2017.35) (PMID:28481368) (PMCID:PMC5523068)
King, J. et al. (2017) Sorafenib for the treatment of advanced hepatocellular cancer – a UK audit. Clinical Oncology, 29(4), pp. 256-262. (doi: 10.1016/j.clon.2016.11.012) (PMID:27964898)
Previdi, M. C., Carotenuto, P., Zito, D., Pandolfo, R. and Braconi, C. (2017) Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncology, 13(5), pp. 443-453. (doi: 10.2217/fon-2016-0253) (PMID:27841659) (PMCID:PMC5253462)
2016
Trevisani, F. et al. (2016) MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 115(11), pp. 1343-1350. (doi: 10.1038/bjc.2016.329) (PMID:27802451) (PMCID:PMC5129818)
Sclafani, F. et al. (2016) Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 37(9), pp. 852-857. (doi: 10.1093/carcin/bgw073) (PMID:27381831) (PMCID:PMC5008250)
Smyth, E. C. et al. (2016) Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. Journal of Clinical Oncology, 34(23), pp. 2721-2727. (doi: 10.1200/JCO.2015.65.7692) (PMID:27298411) (PMCID:PMC5019747)
Lupini, L. et al. (2016) Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 7(21), pp. 31361-31371. (doi: 10.18632/oncotarget.8913) (PMID:27120784) (PMCID:PMC5058762)
Khan, K. et al. (2016) miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 7(11), pp. 12672-12681. (doi: 10.18632/oncotarget.7208) (PMID:26862857) (PMCID:PMC4914313)
Carotenuto, P. et al. (2016) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 66(7), pp. 1268-1277. (doi: 10.1136/gutjnl-2016-312278) (PMID:27618837) (PMCID:PMC5530482)
2015
Sclafani, F. et al. (2015) Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 26(9), pp. 1936-1941. (doi: 10.1093/annonc/mdv285) (PMID:26162609) (PMCID:PMC4551162)
Ghidini, M. and Braconi, C. (2015) Non-coding RNAs in primary liver cancer. Frontiers in Medicine, 2, 36. (doi: 10.3389/fmed.2015.00036) (PMID:26131450) (PMCID:PMC4469108)
Joensuu, H. et al. (2015) KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. Journal of Clinical Oncology, 33(6), pp. 634-642. (doi: 10.1200/JCO.2014.57.4970) (PMID:25605837)
2014
Fassan, M. et al. (2014) Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 5(16), pp. 7162-7171. (doi: 10.18632/oncotarget.2249) (PMID:25216530) (PMCID:PMC4196192)
Valeri, N. et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell, 25(4), pp. 469-483. (doi: 10.1016/j.ccr.2014.03.006) (PMID:24735923) (PMCID:PMC3995091)
2013
Valeri, N. et al. (2013) microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer. Lancet, 381(Sup 1), S17. (doi: 10.1016/S0140-6736(13)60457-2)
2012
Braconi, C. and Patel, T. (2012) Non-coding RNAs as therapeutic targets in hepatocellular cancer. Current Cancer Drug Targets, 12(9), pp. 1073-1080. (doi: 10.2174/156800912803987904) (PMID:22873215) (PMCID:PMC3916140)
Kogure, T., Costinean, S., Yan, I., Braconi, C. , Croce, C. and Patel, T. (2012) Hepatic miR-29ab1 expression modulates chronic hepatic injury. Journal of Cellular and Molecular Medicine, 16(11), pp. 2647-2654. (doi: 10.1111/j.1582-4934.2012.01578.x) (PMID:22469499) (PMCID:PMC3923513)
Dunlop, M. G. et al. (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44(7), pp. 770-776. (doi: 10.1038/ng.2293) (PMID:22634755) (PMCID:PMC4747430)
Joensuu, H. et al. (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncology, 13(3), pp. 265-274. (doi: 10.1016/S1470-2045(11)70299-6) (PMID:22153892)
Valeri, N. et al. (2012) Anti-miR-135b in colon cancer treatment: results from a preclinical study. Journal of Clinical Oncology, 30(S4), p. 457. (doi: 10.1200/jco.2012.30.4_suppl.457)
2011
Braconi, C. , Henry, J. C., Kogure, T., Schmnittgen, T. and Patel, T. (2011) The role of microRNAs in human liver cancers. Seminars in Oncology, 38(6), pp. 752-763. (doi: 10.1053/j.seminoncol.2011.08.001) (PMID:22082761) (PMCID:PMC3928803)
Braconi, C. , Kogure, T., Valeri, N., Huang, N., Nuovo, G., Costinean, S., Negrini, M., Miotto, E., Croce, C.M. and Patel, T. (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene, 30(47), pp. 4750-4756. (doi: 10.1038/onc.2011.193) (PMID:21625215) (PMCID:PMC4292930)
Kogure, T., Lin, W.-L., Yan, I. K., Braconi, C. and Patel, T. (2011) Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology, 54(4), pp. 1237-1248. (doi: 10.1002/hep.24504) (PMID:21721029) (PMCID:PMC3310362)
Braconi, C. , Valeri, N., Kogure, T., Gasparini, P., Huang, N., Nuovo, G.J., Terracciano, L., Croce, C.M. and Patel, T. (2011) Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 108(2), pp. 786-791. (doi: 10.1073/pnas.1011098108)
2010
Braconi, C. , Swenson, E., Kogure, T., Huang, N. and Patel, T. (2010) Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS ONE, 5(12), e15195. (doi: 10.1371/journal.pone.0015195) (PMID:21179572) (PMCID:PMC3002961)
Valeri, N. et al. (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America, 107(49), pp. 21098-21103. (doi: 10.1073/pnas.1015541107) (PMID:21078976) (PMCID:PMC3000294)
Braconi, C. and Patel, T. (2010) Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infectious Disease Clinics of North America, 24(4), pp. 871-884. (doi: 10.1016/j.idc.2010.07.006) (PMID:20937455) (PMCID:PMC2954129)
Valeri, N. et al. (2010) Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 107(15), pp. 6982-6987. (doi: 10.1073/pnas.1002472107) (PMID:20351277) (PMCID:PMC2872463)
Braconi, C. , Huang, N. and Patel, T. (2010) MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology, 51(3), pp. 881-890. (doi: 10.1002/hep.23381) (PMID:20146264) (PMCID:PMC3902044)
Braconi, C. , Valeri, N., Gasparini, P., Huang, N., Taccioli, C., Nuovo, G., Suzuki, T., Croce, C. M. and Patel, T. (2010) Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clinical Cancer Research, 16(3), pp. 957-966. (doi: 10.1158/1078-0432.CCR-09-2123) (PMID:20103677) (PMCID:PMC2818698)
2009
Braconi, C. , Meng, F., Swenson, E., Khrapenko, L., Huang, N. and Patel, T. (2009) Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer, 115(16), pp. 3738-3748. (doi: 10.1002/cncr.24417) (PMID:19514085)
Lang, M., Henson, R., Braconi, C. and Patel, T. (2009) Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver International, 29(5), pp. 670-677. (doi: 10.1111/j.1478-3231.2009.01984.x) (PMID:19226332) (PMCID:PMC3903791)
2008
Braconi, C. , Bracci, R. and Cellerino, R. (2008) Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Current Cancer Drug Targets, 8(5), pp. 359-366. (doi: 10.2174/156800908785133169) (PMID:18690842)
Braconi, C. , Bracci, R., Bearzi, I., Bianchi, F., Sabato, S., Mandolesi, A., Belvederesi, L., Cascinu, S., Valeri, N. and Cellerino, R. (2008) Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Annals of Oncology, 19(7), pp. 1293-1298. (doi: 10.1093/annonc/mdn040) (PMID:18372285)
Braconi, C. and Patel, T. (2008) MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology, 47(6), pp. 1807-1809. (doi: 10.1002/hep.22326) (PMID:18506877)
Braconi, C. et al. (2008) KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Annals of Oncology, 19(4), pp. 706-710. (doi: 10.1093/annonc/mdm503) (PMID:18187489)
2006
Beradi, R. et al. (2006) Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Annals of Oncology, 17(11), pp. 1661-1664. (doi: 10.1093/annonc/mdl285) (PMID:16968873)
Scartozzi, M. et al. (2006) Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori, 92(5), pp. 384-388. (doi: 10.1177/030089160609200503) (PMID:17168429)
Battelli, N. et al. (2006) Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. American Journal of Clinical Oncology, 29(4), pp. 380-384. (doi: 10.1097/01.coc.0000221356.81769.52) (PMID:16891866)
2005
Berardi, R. et al. (2005) Paraneoplastic syndromes: a review Le sindromi paraneoplastiche: Revisione critica della letteratura. Clinica Terapeutica, 156(6), pp. 281-288. (PMID:16463565)
Articles
Kendall, T., Overi, D., Guido, M., Braconi, C. , Banales, J., Cardinale, V., Gaudio, E., Groot Koerkamp, B. and Carpino, G. (2024) Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma. JHEP Reports, 6(6), 101067. (doi: 10.1016/j.jhepr.2024.101067) (PMID:38699072) (PMCID:PMC11060959)
Zanuso, V., Nash, T., Casolino, R., Armstrong, G., Pallise, O., Milne, J. and Braconi, C. (2024) Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic. BMC Cancer, 24(1), 597. (doi: 10.1186/s12885-024-12279-6) (PMID:38755562) (PMCID:PMC11097428)
O’Rourke, C. J. et al. (2024) Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut, 73(3), pp. 496-508. (doi: 10.1136/gutjnl-2023-330748) (PMID:37758326) (PMCID:PMC10894814)
Zanuso, V., Rimassa, L. and Braconi, C. (2023) The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology, (doi: 10.1097/HEP.0000000000000572) (PMID:37695554) (Early Online Publication)
Vita, F., Olaizola Rebè, I., Amato, F., Rae, C. , Marco, S., Banales, J. M. and Braconi, C. (2023) Heterogeneity of cholangiocarcinoma immune biology. Cells, 12(6), 846. (doi: 10.3390/cells12060846) (PMID:36980187) (PMCID:PMC10047186)
Raggi, C., Taddei, M. L., Rae, C. , Braconi, C. and Marra, F. (2022) Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 77(3), pp. 849-864. (doi: 10.1016/j.jhep.2022.04.038) (PMID:35594992)
Muñoz‐Martínez, S. et al. (2022) Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study. Liver International, 42(8), pp. 1891-1901. (doi: 10.1111/liv.15320) (PMID:35608939)
Colyn, L. et al. (2022) New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 41, 183. (doi: 10.1186/s13046-022-02386-2) (PMID:35619118) (PMCID:PMC9134609)
Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)
Casolino, R. et al. (2022) Bridging the equity gap in patient education: the biliary tract cancer BABEL project. Lancet Oncology, 23(5), pp. 568-570. (doi: 10.1016/S1470-2045(22)00143-7) (PMID:35489338)
Izquierdo-Sanchez, L. et al. (2022) Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 76(5), pp. 1109-1121. (doi: 10.1016/j.jhep.2021.12.010) (PMID:35167909)
Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)
Lampis, A. et al. (2021) MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 28, pp. 2970-2982. (doi: 10.1038/s41418-021-00820-0) (PMID:34226680) (PMCID:PMC8481293)
Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)
Rae, C. , Amato, F. and Braconi, C. (2021) Patient-derived organoids as a model for cancer drug discovery. International Journal of Molecular Sciences, 22(7), 3483. (doi: 10.3390/ijms22073483) (PMID:33801782) (PMCID:PMC8038043)
Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)
Ofoeyeno, N., Ekpenyong, E. and Braconi, C. (2021) Pathogenetic role and clinical implications of regulatory RNAs in biliary tract cancer. Cancers, 13(1), 12. (doi: 10.3390/cancers13010012) (PMID:33375055) (PMCID:PMC7792779)
Pea, A., Jamieson, N. B. and Braconi, C. (2021) Biology and clinical application of regulatory RNAs in hepatocellular carcinoma. Hepatology, 73(S1), pp. 38-48. (doi: 10.1002/hep.31225) (PMID:32160335)
Marin, J. J. G. et al. (2020) Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 123, pp. 1047-1059. (doi: 10.1038/s41416-020-0987-3) (PMID:32694694)
Carotenuto, P. et al. (2020) Modulation of biliary cancer chemo‐resistance through microRNA‐mediated rewiring of the expansion of CD133+ cells. Hepatology, 72(3), pp. 982-996. (doi: 10.1002/hep.31094) (PMID:31879968) (PMCID:PMC7590111)
McNamara, M. G. et al. (2020) NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 16(16), pp. 1069-1081. (doi: 10.2217/fon-2020-0247) (PMID:32374623)
Amato, F., Rae, C. , Prete, M. G. and Braconi, C. (2020) Cholangiocarcinoma disease modelling through patients derived organoids. Cells, 9(4), 832. (doi: 10.3390/cells9040832) (PMID:32235647) (PMCID:PMC7226733)
Salati, M. et al. (2019) The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. European Journal of Cancer, 117, pp. 84-90. (doi: 10.1016/j.ejca.2019.05.030) (PMID:31276980)
Salati, M., Valeri, N., Spallanzani, A., Braconi, C. and Cascinu, S. (2019) Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 45(8), pp. 1479-1482. (doi: 10.1016/j.ejso.2018.11.006) (PMID:30448343)
Anandappa, G. et al. (2019) miR-31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. Clinical Cancer Research, 25(13), pp. 3830-3838. (doi: 10.1158/1078-0432.ccr-18-3769) (PMID:30952636)
Banales, J. M., Cardinale, V., Macias, R., Andersen, J. B., Braconi, C. , Carpino, G., Alvaro, D. and Calvisi, D. F. (2019) Cholangiocarcinoma: state‐of‐the‐art knowledge and challenges. Liver International, 39(S1), pp. 5-6. (doi: 10.1111/liv.14101) (PMID:31111668)
Braconi, C. , Roessler, S., Kruk, B., Lammert, F., Krawczyk, M. and Andersen, J. B. (2019) Molecular perturbations in cholangiocarcinoma: is it time for precision medicine? Liver International, 39(S1), pp. 32-42. (doi: 10.1111/liv.14085) (PMID:30829432)
Khan, K. et al. (2019) Efficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience. Clinical Colorectal Cancer, 18(1), 64-71.e1. (doi: 10.1016/j.clcc.2018.09.010) (PMID:30404764)
Fassan, M. et al. (2019) miR-224 is significantly upregulated and targets caspase-3 and caspase-7 during colorectal carcinogenesis. Translational Oncology, 12(2), pp. 282-291. (doi: 10.1016/j.tranon.2018.10.013) (PMID:30448733) (PMCID:PMC6240712)
Salati, M. and Braconi, C. (2019) Noncoding RNA in cholangiocarcinoma. Seminars in Liver Disease, 39(1), pp. 13-25. (doi: 10.1055/s-0038-1676097) (PMID:30536290)
Khan, K. H. et al. (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discovery, 8(10), pp. 1270-1285. (doi: 10.1158/2159-8290.CD-17-0891) (PMID:30166348) (PMCID:PMC6380469)
Khan, K. et al. (2018) Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 67(8), pp. 1484-1492. (doi: 10.1136/gutjnl-2017-314178) (PMID:28790159) (PMCID:PMC6204951)
Saraggi, D. et al. (2018) MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. Pathology: Research and Practice, 214(6), pp. 835-839. (doi: 10.1016/j.prp.2018.04.018) (PMID:29731265)
Lampis, A. et al. (2018) MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology, 154(4), 1066-1079.e5. (doi: 10.1053/j.gastro.2017.10.043) (PMID:29113809) (PMCID:PMC5863695)
Vlachogiannis, G. et al. (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359(6378), pp. 920-926. (doi: 10.1126/science.aao2774) (PMID:29472484) (PMCID:PMC6112415)
Sclafani, F. et al. (2018) KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 8, 1445. (doi: 10.1038/s41598-018-19212-5) (PMID:29362371) (PMCID:PMC5780472)
Moorcraft, S. Y. et al. (2018) Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Annals of Oncology, 29(1), pp. 230-236. (doi: 10.1093/annonc/mdx631) (PMID:29361134)
Ghidini, M. et al. (2017) Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 86, pp. 158-165. (doi: 10.1016/j.ejca.2017.09.005) (PMID:28988016) (PMCID:PMC5699791)
Ghidini, M., Tomasello, G., Botticelli, A., Barni, S., Zabbialini, G., Seghezzi, S., Passalacqua, R., Braconi, C. and Petrelli, F. (2017) Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB, 19(9), pp. 741-748. (doi: 10.1016/j.hpb.2017.05.010) (PMID:28684194)
Kayhanian, H., Smyth, E. C. and Braconi, C. (2017) Emerging molecular targets and therapy for cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 9(7), pp. 268-280. (doi: 10.4251/wjgo.v9.i7.268) (PMID:28808500) (PMCID:PMC5534395)
Lote, H. et al. (2017) Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of Oncology, 28(6), pp. 1243-1249. (doi: 10.1093/annonc/mdx074) (PMID:28327965) (PMCID:PMC5452067)
Pepe, F., Pagotto, S., Soliman, S., Rossi, C., Lanuti, P., Braconi, C. , Mariani-Costantini, R., Visone, R. and Veronese, A. (2017) Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells. Oncogenesis, 6(5), e328. (doi: 10.1038/oncsis.2017.35) (PMID:28481368) (PMCID:PMC5523068)
King, J. et al. (2017) Sorafenib for the treatment of advanced hepatocellular cancer – a UK audit. Clinical Oncology, 29(4), pp. 256-262. (doi: 10.1016/j.clon.2016.11.012) (PMID:27964898)
Previdi, M. C., Carotenuto, P., Zito, D., Pandolfo, R. and Braconi, C. (2017) Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncology, 13(5), pp. 443-453. (doi: 10.2217/fon-2016-0253) (PMID:27841659) (PMCID:PMC5253462)
Trevisani, F. et al. (2016) MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 115(11), pp. 1343-1350. (doi: 10.1038/bjc.2016.329) (PMID:27802451) (PMCID:PMC5129818)
Sclafani, F. et al. (2016) Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 37(9), pp. 852-857. (doi: 10.1093/carcin/bgw073) (PMID:27381831) (PMCID:PMC5008250)
Smyth, E. C. et al. (2016) Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. Journal of Clinical Oncology, 34(23), pp. 2721-2727. (doi: 10.1200/JCO.2015.65.7692) (PMID:27298411) (PMCID:PMC5019747)
Lupini, L. et al. (2016) Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 7(21), pp. 31361-31371. (doi: 10.18632/oncotarget.8913) (PMID:27120784) (PMCID:PMC5058762)
Khan, K. et al. (2016) miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 7(11), pp. 12672-12681. (doi: 10.18632/oncotarget.7208) (PMID:26862857) (PMCID:PMC4914313)
Carotenuto, P. et al. (2016) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 66(7), pp. 1268-1277. (doi: 10.1136/gutjnl-2016-312278) (PMID:27618837) (PMCID:PMC5530482)
Sclafani, F. et al. (2015) Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 26(9), pp. 1936-1941. (doi: 10.1093/annonc/mdv285) (PMID:26162609) (PMCID:PMC4551162)
Ghidini, M. and Braconi, C. (2015) Non-coding RNAs in primary liver cancer. Frontiers in Medicine, 2, 36. (doi: 10.3389/fmed.2015.00036) (PMID:26131450) (PMCID:PMC4469108)
Joensuu, H. et al. (2015) KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. Journal of Clinical Oncology, 33(6), pp. 634-642. (doi: 10.1200/JCO.2014.57.4970) (PMID:25605837)
Fassan, M. et al. (2014) Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 5(16), pp. 7162-7171. (doi: 10.18632/oncotarget.2249) (PMID:25216530) (PMCID:PMC4196192)
Valeri, N. et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell, 25(4), pp. 469-483. (doi: 10.1016/j.ccr.2014.03.006) (PMID:24735923) (PMCID:PMC3995091)
Valeri, N. et al. (2013) microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer. Lancet, 381(Sup 1), S17. (doi: 10.1016/S0140-6736(13)60457-2)
Braconi, C. and Patel, T. (2012) Non-coding RNAs as therapeutic targets in hepatocellular cancer. Current Cancer Drug Targets, 12(9), pp. 1073-1080. (doi: 10.2174/156800912803987904) (PMID:22873215) (PMCID:PMC3916140)
Kogure, T., Costinean, S., Yan, I., Braconi, C. , Croce, C. and Patel, T. (2012) Hepatic miR-29ab1 expression modulates chronic hepatic injury. Journal of Cellular and Molecular Medicine, 16(11), pp. 2647-2654. (doi: 10.1111/j.1582-4934.2012.01578.x) (PMID:22469499) (PMCID:PMC3923513)
Dunlop, M. G. et al. (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44(7), pp. 770-776. (doi: 10.1038/ng.2293) (PMID:22634755) (PMCID:PMC4747430)
Joensuu, H. et al. (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncology, 13(3), pp. 265-274. (doi: 10.1016/S1470-2045(11)70299-6) (PMID:22153892)
Valeri, N. et al. (2012) Anti-miR-135b in colon cancer treatment: results from a preclinical study. Journal of Clinical Oncology, 30(S4), p. 457. (doi: 10.1200/jco.2012.30.4_suppl.457)
Braconi, C. , Henry, J. C., Kogure, T., Schmnittgen, T. and Patel, T. (2011) The role of microRNAs in human liver cancers. Seminars in Oncology, 38(6), pp. 752-763. (doi: 10.1053/j.seminoncol.2011.08.001) (PMID:22082761) (PMCID:PMC3928803)
Braconi, C. , Kogure, T., Valeri, N., Huang, N., Nuovo, G., Costinean, S., Negrini, M., Miotto, E., Croce, C.M. and Patel, T. (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene, 30(47), pp. 4750-4756. (doi: 10.1038/onc.2011.193) (PMID:21625215) (PMCID:PMC4292930)
Kogure, T., Lin, W.-L., Yan, I. K., Braconi, C. and Patel, T. (2011) Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology, 54(4), pp. 1237-1248. (doi: 10.1002/hep.24504) (PMID:21721029) (PMCID:PMC3310362)
Braconi, C. , Valeri, N., Kogure, T., Gasparini, P., Huang, N., Nuovo, G.J., Terracciano, L., Croce, C.M. and Patel, T. (2011) Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 108(2), pp. 786-791. (doi: 10.1073/pnas.1011098108)
Braconi, C. , Swenson, E., Kogure, T., Huang, N. and Patel, T. (2010) Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS ONE, 5(12), e15195. (doi: 10.1371/journal.pone.0015195) (PMID:21179572) (PMCID:PMC3002961)
Valeri, N. et al. (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America, 107(49), pp. 21098-21103. (doi: 10.1073/pnas.1015541107) (PMID:21078976) (PMCID:PMC3000294)
Braconi, C. and Patel, T. (2010) Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infectious Disease Clinics of North America, 24(4), pp. 871-884. (doi: 10.1016/j.idc.2010.07.006) (PMID:20937455) (PMCID:PMC2954129)
Valeri, N. et al. (2010) Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 107(15), pp. 6982-6987. (doi: 10.1073/pnas.1002472107) (PMID:20351277) (PMCID:PMC2872463)
Braconi, C. , Huang, N. and Patel, T. (2010) MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology, 51(3), pp. 881-890. (doi: 10.1002/hep.23381) (PMID:20146264) (PMCID:PMC3902044)
Braconi, C. , Valeri, N., Gasparini, P., Huang, N., Taccioli, C., Nuovo, G., Suzuki, T., Croce, C. M. and Patel, T. (2010) Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clinical Cancer Research, 16(3), pp. 957-966. (doi: 10.1158/1078-0432.CCR-09-2123) (PMID:20103677) (PMCID:PMC2818698)
Braconi, C. , Meng, F., Swenson, E., Khrapenko, L., Huang, N. and Patel, T. (2009) Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer, 115(16), pp. 3738-3748. (doi: 10.1002/cncr.24417) (PMID:19514085)
Lang, M., Henson, R., Braconi, C. and Patel, T. (2009) Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver International, 29(5), pp. 670-677. (doi: 10.1111/j.1478-3231.2009.01984.x) (PMID:19226332) (PMCID:PMC3903791)
Braconi, C. , Bracci, R. and Cellerino, R. (2008) Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Current Cancer Drug Targets, 8(5), pp. 359-366. (doi: 10.2174/156800908785133169) (PMID:18690842)
Braconi, C. , Bracci, R., Bearzi, I., Bianchi, F., Sabato, S., Mandolesi, A., Belvederesi, L., Cascinu, S., Valeri, N. and Cellerino, R. (2008) Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Annals of Oncology, 19(7), pp. 1293-1298. (doi: 10.1093/annonc/mdn040) (PMID:18372285)
Braconi, C. and Patel, T. (2008) MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology, 47(6), pp. 1807-1809. (doi: 10.1002/hep.22326) (PMID:18506877)
Braconi, C. et al. (2008) KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Annals of Oncology, 19(4), pp. 706-710. (doi: 10.1093/annonc/mdm503) (PMID:18187489)
Beradi, R. et al. (2006) Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Annals of Oncology, 17(11), pp. 1661-1664. (doi: 10.1093/annonc/mdl285) (PMID:16968873)
Scartozzi, M. et al. (2006) Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori, 92(5), pp. 384-388. (doi: 10.1177/030089160609200503) (PMID:17168429)
Battelli, N. et al. (2006) Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. American Journal of Clinical Oncology, 29(4), pp. 380-384. (doi: 10.1097/01.coc.0000221356.81769.52) (PMID:16891866)
Berardi, R. et al. (2005) Paraneoplastic syndromes: a review Le sindromi paraneoplastiche: Revisione critica della letteratura. Clinica Terapeutica, 156(6), pp. 281-288. (PMID:16463565)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Identifying therapeutic opportunities for Bilary Cancers by investigating the role of Monocytes in drug response
AMMF - The Cholangiocarcinoma Charity
2024 - 2025
- CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2023
- Dissecting the transcriptomic and phenotypic reprogramming of monocytes that mediate chemoresistance in cholangiocarcinoma.
Office of the Chief Scientific Adviser
2022 - 2025
- CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2024
- LivRnCODE Non coding RNA in liver cancer
European Commission
2013 - 2017
- The role of Transcribed Ultraconserved Regions in Hepatocarcinoma
Chief Scientist Office
2013 - 2014
- The role of Transcribed Ultraconserved Regions in Hepatocarcinoma
Scottish Funding Council
2013 - 2017
HepatoBiliary and Pancreatic Oncology Group
Our research encompasses hepato-pancreatico-biliary tumours, with a specific focus on Biliary Tract Cancers, and aims at integrating genomics, epigenomics and patient derived models for the identification of novel therapeutic targets and biomarkers.
We have developed a research platform on biliary cancers, connecting laboratory research and clinical development to accelerate the field of predictive biomarkers and therapeutics.
If you are interested in joining the HBPO group please email chiara.braconi@glasgow.ac.uk